Overexpression of human insulin-like growth factor II (IGF-II) in transgenic mice does not result in increased overall body growth. The IGF-II overexpression, however, specifically causes growth of the thymus and not of the spleen. We address the question whether the observed differences in growth induction in lymphoid tissues by IGF-II can be related to differences in local IGF binding protein (IGFBP) production, using nonradioactive in situ hybridization and Northern blot analysis. IGFBP-2, -4, and -5 are expressed in both lymphoid tissues of normal mice. The spleen additionally expresses IGFBP-3 and IGFBP-6. IGFBP-1 expression was not detected. Although the expression pattern of the IGFBPs did not change upon IGF-II overexpression, the level of expression changed in a specific manner for each IGFBP. In both the thymus and the spleen of transgenic mice, IGFBP-2 and -5 gene expression was slightly increased, whereas the level of IGFBP-4 expression was not altered. In the spleen, IGFBP-6 expression was not altered by IGF-II overexpression, whereas IGFBP-3 expression was strongly increased. The differences in IGFBP expression, and the difference in response of these IGFBPs to IGF-II overexpression in thymus and spleen suggests an important role of these proteins in growth regulation of both lymphoid tissues. We speculate that an increase of IGFBP-3 expression together with changes in expression of other IGFBPs, inhibits IGF-II stimulated growth in the spleen by an autocrine-/paracrine pathway. (Endocrinology 140: 5876 -5882, 1999) 
T HE INSULIN-LIKE growth factors (IGF-I and -II) are
potent mitogenic and differentiation promoting growth factors (1) . Furthermore, the IGFs can inhibit cell death, induce differentiation and stimulate differentiated functions in several cell types (2) . The IGFs play an important role in pre-and postnatal growth. In rodents, IGF-I is presumed to be important in pre-and postnatal growth, whereas IGF-II only seems to be important in prenatal growth (3, 4) .
IGFs are produced in multiple tissues and can act both in an endocrine and autocrine/paracrine fashion. The activity of IGFs is regulated at various levels, resulting in a complex regulation of IGF bioactivity (2, 5) . Their intracellular effects are mediated predominantly via the type I IGF receptor (6) .
IGFs are present in the circulation and throughout the extracellular space bound to members of high affinity IGF binding proteins (IGFBPs). The availability of the IGFs for their receptor is modulated by these IGFBPs, of which six are cloned and characterized (7, 8) . IGFBP genes are widely expressed in the developing tissues of rodents (9) , sheep (10) , and humans (11) . The IGFBPs act mainly as autocrine and/or paracrine factors at or close to their sites of synthesis (2) . The individual IGFBPs differ in their tissue distribution and may either inhibit or potentiate IGF activity. Furthermore, they differ in their IGF-binding capacity (2, 12) . IGFBP-3 is the major serum carrier of IGFs, in a complex with an acid-labile subunit (ALS) (13) .
Transgenic mice with recombinant human IGF-II under the control of the H-2K b promoter show increased IGF-II serum levels, whereas overall body growth is not affected (14) . The hIGF-II transgene is highly expressed in the two lymphoid tissues, the thymus and the spleen, causing thymic but no splenic growth (14 -16) .
Because there are indications that the IGFBPs regulate actions of locally produced IGFs in lymphoid tissues (5, 17) , we studied the IGFBP expression in the spleen and the thymus of normal and the hIGF-II transgenic mice in situ. The observed differences in IGFBP expression and the difference in response to IGF-II overexpression suggest an important role of the IGFBPs in growth regulation. The IGFBP-3 gene, expressed in the spleen only, is most susceptible to IGF-II overexpression. We speculate that IGFBP-3 plays a prominent paracrine role with respect to the inhibition of the hIGF-II transgene bioactivity in the spleen, by either an IGFdependent or IGF-independent mechanism.
Materials and Methods Materials
All restriction enzymes and modifying enzymes were purchased from Roche Molecular Biochemicals (Mannheim, Germany), as well as the digoxigenin-UTP, anti-digoxigenin Fab-fragments, nitro blue tetrazolium, 5-bromo-4-chloro-3-indolyl-phosphatase, blocking reagent, the Tripure isolation reagent and the Agarose Gel DNA extraction kit. Nylon membranes were purchased from QIAGEN (Westburg, The Netherlands). 
Mice and tissue preparation
hIGF-II transgenic mice were generated by introduction of a human IGF-II gene into FVB/N control mice as described in detail by Van Buul-Offers and colleagues (14) . Throughout the study, the line designated 5Ј-74 (Tg-II), was used for our experiments. As controls normal FVB/N mice were used. The animals were kept under standardized laboratory conditions. The mice were killed by decapitation after ether anesthesia at the age of 4 weeks. Thymus and spleen were dissected, frozen in liquid nitrogen and stored at Ϫ80 C. The protocol received approval of the committee for Animal Experiments of the Medical Faculty, University of Utrecht.
Probes
Digoxigenin-labeled complementary RNA (cRNA) probes. Standard RNA synthesis reactions using T7-or T3-RNA polymerase were carried out using digoxigenin-UTP as substrate (18) . cDNAs encoding human IGF-II (19) and mouse IGFBP-1, -2, -3, -4, -5, and -6 cDNAs, corresponding to amino acid position 100 -133, 98 -258, 137-204, 131-205, 88 -182, 83-140 respectively (9), were used as templates for the synthesis of antisense and/or sense digoxigenin-labeled RNA probes.
[␣ 32 P]dCTP-labeled cDNA probes. Twenty nanograms of gel-purified inserts of plasmids containing mouse IGFBP-2, -3, and -5 cDNA, were radiolabeled with 50 Ci [␣ 32 P]dCTP, using random primed DNA labeling as described by the manufacturer.
In situ hybridization
Tissues used for in situ hybridization were fixed for 18 h in 4% (wt/vol) paraformaldehyde at 4 C, washed in PBS, dehydrated through a series of ethanol and embedded in paraffin.
Paraffin tissue sections (10 m) were dewaxed, hydrated, rinsed in PBS and treated with proteinase K (0.07 U/ml) for 30 min at 37 C and subjected to an acetylation treatment (20) . Sections were rinsed in 2 ϫ SSC and kept in this solution until the start of the hybridization.
Hybridization was performed in a solution containing 50% formamide, 2 ϫ SSC, 1 ϫ Denhardt's solution, 1 g/l yeast RNA and 10% dextran-sulfate and the digoxigenin labeled cRNA probe at a concentration of 500-1500 pg/l. Sections were hybridized overnight at 53 C. After hybridization, sections were washed with 50% formamide in 2 ϫ SSC at 53 C for 30 min and treated with RNase A (1 U/ml) for 30 min at 37 C. Subsequently, sections were rinsed in 2 ϫ SSC, treated with 10% lamb serum for 30 min and incubated with sheep antidigoxigenin Fabfragments coupled to alkaline phosphatase (1:500) for 2 h at room temperature.
Chromogenesis was performed with 0.38 mg/ml nitroblue tetrazolium and 0.19 mg/ml 5-bromo-4-chloro-3-indolyl-phosphatase in the presence of 6% (wt/vol) polyvinylalcohol (21), resulting in a blue precipitate. Sections were counterstained with nuclear fast red, dehydrated through a series of ethanol and mounted with Euparal.
Three to four different animals of each strain were used per analyzed IGFBP messenger RNA (mRNA) and for each probe the in situ hybridization was repeated 5 to 6 times.
Northern blot analysis
RNA extraction. Total RNA was extracted from frozen spleen and thymus from 4 weeks old normal (FVB/N) and hIGF-II transgenic mice, using Tripure solution reagent according to the procedures of the manufacturer, based on the single step acid guanidinium thiocyanate method (22) .
Northern blot analysis. Twenty micrograms of total RNA was separated by electrophoresis in a 1% (wt/vol) agarose/2.2 m formaldehyde gel in 1 ϫ 3-(morpholino) propanesulphonic acid (MOPS) buffer and transferred to a 0.2 m nylon membrane and crosslinked by UV radiation (1200 J).
The membranes were prehybridized for 2 h at 60 C in a solution containing 0.1% SDS, 3 ϫ SSC, 5 ϫ Denhardt's solution, 10% dextransulfate and 5% denaturated salmon sperm DNA. Hybridization was performed at 60 C overnight in the same solution, containing the [␣ 32 P]dCTP-labeled probe. Following hybridization, the membranes were washed to a stringency of 0.2 ϫ SSC, 0.1% (wt/vol) SDS. Membranes were analyzed using the GS-363 Molecular Imager (Bio-Rad Laboratories, Inc. Hercules, CA) and subsequently quantified using the Molecular Analyst software program, version 1.4 (Bio-Rad Laboratories, Inc.). The signals were also visualized by autoradiography on Fuji Photo Film Co., Ltd. RX x-ray film.
Tissues of at least three different animals of each strain were analyzed.
Statistical analysis
Data of the Northern blot analyses were analyzed with Student's two-tailed test. A P value of less than 0.05 was considered statistically significant.
Results

IGFBP expression patterns and changes therein upon IGF-II overexpression
Thymus. Representative thymus sections of 4 weeks old normal and hIGF-II transgenic mice, analyzed with in situ hybridization using specific IGFBP probes, are shown in Fig. 1 .
Control in situ hybridizations of thymus sections of transgenic mice with nonradioactive human IGF-II RNA probe showed very strong staining in the medulla and in a small number of cells in the cortex (Fig. 1B) , whereas hardly any IGF-II transcripts could be detected in the thymus of FVB/N nontransgenic mice (Fig. 1A) . As a control for specific hybridization, sections were hybridized with the corresponding sense RNA probes, which showed no signals (see e.g., Fig.  1C ). In the thymus of normal mice no expression of IGFBP-1, -3, and -6 could be detected (Fig. 1, D-F) . IGFBP-2, -4, and -5 transcripts were present, each showing a unique expression pattern (Fig. 1, G-J) . Transcripts of IGFBP-2 were present in groups of cells, mainly at the boundary of the medulla and the cortex and, at a low level, in the medulla (Fig. 1G) . IGFBP-4 was exclusively detected in the medulla (Fig. 1H) . A similar expression pattern was seen for IGFBP-5 (Fig. 1J) ; however, the number of cells expressing IGFBP-5 was lower than for IGFBP-4. IGFBP-4 and -5 transcripts were detected in single positive cells and not in groups of positive cells as seen for IGFBP-2.
To study the influence of IGF-II overexpression on IGFBP expression, thymus sections of 4 weeks old hIGF-II transgenic mice were analyzed with in situ hybridization (Fig. 1,  K-M) . No expression of IGFBP-1, -3, or -6 could be detected (data not shown). The expression patterns of IGFBP-2, -4, and -5 in the transgenic thymus was similar to that found in the thymus of normal mice (Fig. 1, K-M) . However, the level of expression was slightly increased for IGFBP-2, (cf. Fig. 1 , G and K), and to a higher extent for IGFBP-5 (cf. Fig. 1 , J and M). IGFBP-4 transcripts were present at the same level as in normal mice. Although the shown data suggests a lower level of IGFBP-4 mRNA in the transgenic thymus (Fig. 1L) , most of the performed experiments showed no difference in levels of expression. However, the picture shown was chosen to illustrate the expression pattern.
Spleen. Representative spleen sections of normal and hIGF-II transgenic mice, 4 weeks of age, analyzed with in situ hybridization using specific mouse IGFBP probes are shown in Fig. 2 .
Control in situ hybridizations of spleen sections of the transgenic mice with nonradioactive hIGF-II RNA probe showed high IGF-II transgene expression in the white pulp and a few positively stained cells in the red pulp and/or marginal zone (Fig. 2B) . Spleen sections of the nontransgenic FVB/N control mice showed a very weak IGF-II expression in the red pulp ( Fig. 2A) . In the spleen of normal mice, no IGFBP-1 gene expression could be detected (data not shown). IGFBP-2, -3, -4, -5, and -6 mRNAs were present, each showing a unique expression pattern (Fig. 2, C, D, G-J) . Control sections hybridized with the appropriate sense probes exhibited no signal (data not shown).
IGFBP-2 is expressed at a high level in groups of cells in the red pulp (RP) and at a very low level in the white pulp (WP) (Fig. 2C) . IGFBP-3 transcripts were detected, at a low level, in the inner lining of the marginal zone (MZ) and in some cells in the white pulp, whereas no IGFBP-3 transcripts could be detected in the red pulp (Fig. 2D) . IGFBP-4 transcripts were detected all through in the white pulp only (Fig.  2G) . IGFBP-5 transcripts were detected in the white pulp in sparsely scattered cells and in cells concentrated around the veins. IGFBP-5 expression was also detected at a low level at the exterior part of the red pulp (Fig. 2H) . At the exterior part of the red pulp, also a considerable amount of IGFBP-6 transcripts were detected, whereas lower amounts were detected in the other parts of the red pulp and in the white pulp (Fig.  2J) .
To study the influence of IGF-II overexpression on IGFBP expression, spleen sections of 4-week-old hIGF-II transgenic mice were analyzed with in situ hybridization (Fig. 2 , E, F, K-M). No expression of IGFBP-1 could be detected in the transgenic spleen (data not shown). Although the level of expression of some IGFBPs changed upon IGF-II overexpression, the pattern of expression remained the same, as was observed in the thymus. IGFBP-4 and -6 transcripts were detected at the same level as in normal mice (cf. Fig. 2 , G and K, and J and M, respectively). On the contrary, the level of expression of IGFBP-2, -3, and -5 was increased compared with the expression level in the normal spleen. The expression of IGFBP-2 was slightly increased in the white pulp, Sections were hybridized with antisense digoxigenin-labeled cRNA probes, specific for human IGF-II and mouse IGFBP-1 to -6 as indicated. Sections were further treated as described in Fig. 1 . WP, White pulp; RP, red pulp; MZ, marginal zone. Magnification, 100 times. The black bar in the right corner refers to the actual size of 100 m.
whereas the level of expression in the red pulp was not altered (cf. Fig. 2 , C and E). The expression of IGFBP-5, detected in the red pulp at the edge of the section and in the white pulp, showed an increase in level of expression (cf. Fig.  2 , H and L). IGFBP-3 expression in the marginal zone and the white pulp was strongly increased (cf. Fig. 2, D and F) .
Quantification of changes in IGFBP-3 expression
To quantify the changes in IGFBP-3 expression upon IGF-II overexpression, Northern blot analysis was performed. Total RNA was extracted from the spleen and the thymus of 4-week-old normal and hIGF-II transgenic mice and subsequently hybridized with a mouse IGFBP-3 [␣ 32 P]dCTP-labeled cDNA probe, a representative experiment is shown in Fig. 3A . This revealed a transcript of 2.6 kb (Fig. 3A) , corresponding to an IGFBP-3 transcript length as described previously (23) . This transcript was only present in the spleen of normal and hIGF-II transgenic mice (Fig. 3A,  lanes 4 and 1, respectively) and not in the thymus of either mice strain (Fig. 3A, lanes 2 and 3, respectively) . Quantification of the detected IGFBP-3 transcripts in the normal spleen (n ϭ 3) and hIGF-II transgenic spleen (n ϭ 5), after normalization with the GAPDH mRNA signal, showed a statistically significant increase in level of expression in the transgenic spleen of 1.75 Ϯ 0.11 (Fig. 3B ).
An increase in expression of IGFBP-2 and -5 in hIGF-II transgenic mice in the thymus and spleen is shown with in situ hybridization, although not as strong as seen for IGFBP-3 in the spleen. Quantification of IGFBP-2 and -5 expression using Northern blot analysis showed the presence of IGFBP-2 and -5 mRNA in the spleen and the thymus of normal and hIGF-II transgenic mice, however no statistically significant differences were detected (data not shown).
Discussion
Besides the endocrine actions of IGFs, these hormone peptides can exert actions locally in a variety of tissues and cell types. Tissue-specific regulation of the IGF-bioactivity may be accomplished by the presence of IGFBPs, which are differentially expressed in various tissues (2) . The relative concentration of each IGFBP changes, depending on the physiological and pathological environment (12, 24) . In hIGF-II transgenic mice, both the spleen and the thymus express the hIGF-II gene at a high level (14, 16) , which might therefore induce a change in local IGFBP expression. Furthermore, it was shown that both IGF receptors are present in both organs, enabling IGF-II bioactivity (16) . However, the thymus displayed growth in response to this IGF-II overexpression, whereas the size of the spleen was unaffected, although both organs displayed an increase in CD4 ϩ T cells (15) . To answer the question whether the difference in response to IGF-II overexpression was related to differences in IGFBP expression, we studied the expression of the six IGFBP genes in both lymphoid tissues of normal and hIGF-II transgenic mice.
Normal IGFBP expression patterns in lymphoid organs
Each IGFBP gene has a specific, unique expression pattern in both lymphoid tissues, as shown in this study by nonradioactive in situ hybridization analysis. In both lymphoid tissues, IGFBP-2, -4, and -5 transcripts were detected. In addition to these genes, the spleen expresses the IGFBP-3 and IGFBP-6 gene. IGFBP-4 and -5 displayed a similar expression pattern in both tissues. On the contrary, IGFBP-2 transcripts showed a different localization, and were mainly present in the red pulp of the spleen and at the boundary of the medulla/cortex in the thymus. IGFBP-6 transcripts were mainly detected in the red pulp of the spleen and at a low concentration in the white pulp, colocalizing with IGFBP-2, -4, and IGFBP-5 transcripts. IGFBP-3 transcripts showed a completely different localization, and were present mainly in the marginal zone. Colocalization and differences in localization of certain IGFBPs was previously shown at the tissue level in human fetus, mouse kidney and mouse skeleton (11, 25, 26) . In both the spleen and the thymus, the IGFBP transcripts are detected in mature lymphocytes, based on the localization and morphology of the positively stained cells. IGFBP-3 transcripts, however, are predominantly present in the macrophages of the marginal zone, based on staining results with an antibody specific for the detection of macrophages (MOMA) present in the marginal zone (Koster, personal communication), although a low expression in lymphocytes in the white pulp is also shown.
The observed differences in IGFBP expression in the spleen and the thymus of normal mice suggest a putative difference in mediating local IGF activity in these tissues.
IGF-II induced changes in IGFBP expression
Previous findings in the literature already suggested a direct relationship between IGFs and IGFBPs at the serum level (27) (28) (29) (30) , especially of IGF-II on IGFBP-3 in Pit-1 deficient Snell dwarf mice (30) . In this study, a direct relationship between IGF-II and a number of IGFBPs is shown at tissue level, varying in different tissues. In spleen and thymus, IGFBP-2 and -5 mRNA are positively correlated with IGF-II mRNA, as previously shown also at the protein level for IGFBP-2 in serum of PEPCK-IGF-II transgenic mice (27) and for IGFBP-5 in human serum (28) . IGFBP-4 mRNA does not seem to be correlated with IGF-II mRNA levels, in accordance with data concerning the protein in human serum (29) . IGFBP-6 expression, only present in the spleen, seems also not to be correlated with levels of IGF-II mRNA, as shown here in this study. The IGF-II-induced changes in IGFBP expression are summarized in Table 1 .
Previous studies in IGF-I transgenic mice have shown an in vivo temporally and spatially relationship between IGF-I mRNA and IGFBP-5 mRNA, in the brain (31) . This previous study with IGF-I transgenic mice and our study with IGF-II transgenic mice, indicate the possibility of tissue-specific direct regulation of the expression of IGFBPs by their ligands, the IGFs.
In the spleen, the IGFBP-3 gene seems to be most susceptible to IGF-II overexpression, which is confirmed by Northern blot analysis. hIGF-II transgenic Snell dwarf mice also show an increase in IGFBP-3 mRNA in the spleen and an increase in IGFBP-3 serum levels, compared with normal Snell dwarf mice (14; unpublished results). In these hIGF-II transgenic Snell dwarf mice no IGF-I is present (14, 24) . Furthermore, IGF-I serum levels are not elevated in normal hIGF-II transgenic mice (14) , indicating that the increase of IGFBP-3 in hIGF-II transgenic normal and Snell dwarf mice cannot be caused by IGF-I. In addition, IGF-II treatment of dwarf mice results in a pronounced increase of IGFBP-3 in serum (30) .
Role of IGFBP-3 in growth regulation
As discussed above, the main difference between the spleen and the thymus in terms of regulation of IGFBP expression by IGF-II is the considerable increase in IGFBP-3 expression in the macrophages of the marginal zone of the spleen. The number of these macrophages in the marginal zone is not increased in the spleen of hIGF-II transgenic mice, indicating that the increase in IGFBP-3 expression is due to constitutive IGF-II expression and not due to changes in morphology of the marginal zone. The presence and upregulation of IGFBP-3 is independent of GH and/or IGF-I, since similar results were obtained in hIGF-II transgenic Snell dwarf mice (unpublished results). The IGF-II-induced increase in IGFBP-3 expression can have effects on several mechanisms involving growth regulation. First, it has been demonstrated in vitro (32) (33) (34) (35) and in vivo (36) , that IGFBP-3 can act as a negative growth regulator of cell proliferation by sequestering the IGF-II. Thus, the spleen-specific enhanced IGFBP-3 expression might inhibit the growth inducing effect of the IGF-II transgene in the spleen by sequestering IGF-II and thereby diminishing the IGF-II bioactivity. Observations in IGFBP-3 transgenic mice (37) seem to contradict this speculation, as in these mice an increase of IGFBP-3 serum levels results in growth of the spleen. However, no IGFBP-3 mRNA could be detected in the spleen of these mice, excluding high levels of IGFBP-3 in the spleen. Furthermore, the enhanced IGFBP-3 serum levels were of the binary complex. As this IGF-IGFBP-3 complex can cross the capillary endothelium, enhanced serum levels can transport more IGF-I or -II into the spleen causing enhanced IGF-bioactivity. Thus, in these animals, IGFBP-3 probably acts mainly by an endocrine pathway, instead of the proposed auto-/paracrine way of action in our transgenics.
Besides the growth-inhibitory effect of IGFBP-3 caused by regulating the availability of free IGFs, IGFBP-3 can also induce growth arrest (38 -40) and apoptosis, mediated through a pathway independent of the IGF-IGF-receptor interaction (41) . The relatively high concentrations of IGFBP-3 in transgenic spleen could have such an IGF-II independent activity. Therefore, although the influence of other IGFBPs on the IGF-II bioactivity should not be neglected, the considerable increase in IGFBP-3 mRNA and selective expression in the spleen, suggest that this IGFBP plays a prominent role in the reduction of the growth promoting effect of IGF-II in the spleen. Changes of growth and IGF-II and IGFBP expression in the thymus and the spleen of 4 weeks old hIGF-II transgenic mice, as compared to normal mice are indicated. The size of the arrow(s) is representative for the observed increase in level of expression. The increase in IGFBP-2 and -5 is based on the in situ results, whereas the increase of IGFBP-3 is based on the in situ and the Northern blot analysis.
In conclusion, in this study it has been shown that the thymus and the spleen display a tissue-specific IGFBP expression. In all likelihood, it is the difference in IGFBP expression that causes a difference in local IGF-II bioactivity, resulting in a strong growth promoting effect of IGF-II in the thymus and hardly any in the spleen. This suggests that the growth-inducing effect of IGF-II depends on its local environment.
